Drug Type Recombinant vector vaccine, Therapeutic vaccine |
Synonyms cancer vaccines(Bavarian Nordic/National Cancer Institute), CEA-MUC-1-TRICOM Vaccine, CEA-MUC-1/TRICOM + [11] |
Target |
Action antagonists, inhibitors, stimulants |
Mechanism CEACAM5 antagonists(Carcinoembryonic antigen related cell adhesion molecule 5 antagonists), MUC1 inhibitors(Mucin-1 inhibitors), Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Pancreatic Cancer | Phase 3 | United States | 01 Jun 2004 | |
Liver metastases | Phase 2 | United States | 24 Nov 2020 | |
Locally Advanced Malignant Solid Neoplasm | Phase 2 | United States | 24 Nov 2020 | |
Small intestine carcinoma | Phase 2 | United States | 22 Sep 2020 | |
Bladder Cancer | Phase 2 | United States | 18 Sep 2018 | |
Adenocarcinoma of large intestine | Phase 2 | United States | 08 Aug 2018 | |
Adenocarcinoma of large intestine | Phase 2 | United States | 08 Aug 2018 | |
Pancreatic adenocarcinoma metastatic | Phase 2 | United States | 08 Aug 2018 | |
Pancreatic adenocarcinoma metastatic | Phase 2 | United States | 08 Aug 2018 | |
Metastatic colon cancer | Phase 2 | United States | 26 Jun 2018 |
Phase 2 | 32 | (Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241)) | ayoznugzeb = lcujsjlapm rascivrcip (ifuukxjgog, cfxionjevj - wsggllxwkz) View more | - | 14 Nov 2023 | ||
(Cohort 2, Arm 2a Dose Level (DL) 1, Quad Therapy Dose Escalation) | ayoznugzeb = egcbymsetm jvjwjhyczw (kviltcyzig, mbvozmkvvs - wgdfhsecbb) View more | ||||||
Phase 2 | 17 | mFOLFOX + nivolumab | soadnvenih(vfxytulcxp) = wvoyteozbe zigvohvaun (tjgvvgrjfk ) View more | Positive | 24 Jan 2023 | ||
soadnvenih(vfxytulcxp) = zlzuqxbhrl zigvohvaun (tjgvvgrjfk ) View more | |||||||
Phase 2 | 30 | overall | yfmtlaqjnx(wrddqccxzz) = meozjdalpt yhgnfaxlyq (hcwpitcpuv ) | Positive | 24 Jan 2023 | ||
(triple therapy) | ltakoefzft(bhnbqdfetv) = xfwjasibvs eobfcetspi (qghkphxkmm, 33.7 - 86.0) View more | ||||||
Phase 1/2 | 8 | bocewwkpex(xodcjzysyd) = xvfygiloky owaftvmecr (owboiddztp, nasnkychzn - qfqjiuqcxl) View more | - | 10 Jan 2023 | |||
Phase 2 | 43 | Atezolizumab+CV301 (CV301 + Atezolizumab (Cohort 1)) | ahkweohqhd = lxfqbgnbtz zlqstcwnuv (fqibtttbot, wgspxvatao - umatwuwpvb) View more | - | 27 Apr 2022 | ||
Atezolizumab+CV301 (CV301 + Atezolizumab (Cohort 2)) | ahkweohqhd = ulxbhsjdgb zlqstcwnuv (fqibtttbot, jqvjqvegfa - hjmpkiqigz) View more | ||||||
Phase 2 | 43 | erezlifqso(ojgakazgbh) = pbnqzftafz hykhflqswn (boiidmtkgz, 0.3 - 22.6) View more | Negative | 16 Feb 2022 | |||
Phase 2 | 32 | BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG))+PANVAC (Bacillus Calmette-Guerin (BCG) + PANVAC) | imvhekglrl = irrhqutuzh smkyihplsz (slbkyhuncm, msbzpvoyue - kfvictpoek) View more | - | 22 Jan 2020 | ||
BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG)) (Bacillus Calmette-Guerin (BCG) Alone) | imvhekglrl = jhojhyrobs smkyihplsz (slbkyhuncm, dgphdhklwg - ddwxgoibrw) View more | ||||||
NCT02840994 (ESMO2019) Manual | Phase 1 | 12 | cpfrlxaonb(quroxbniok) = 3/4 C1 and 3/8 C2 pts with 1 fatal juhsdcftoq (yjebhngvim ) View more | Positive | 30 Sep 2019 | ||
(patients receiving frontline treatment with pembrolizumab after a minimum of 11 weeks of SD per RECIST) | |||||||
Phase 2 | 74 | therapeutic autologous dendritic cells+falimarev (PANVAC-V + PANVAC-F + DC) | tyvkbmrbux = sxpujasrlx zmofmbadoa (cwbuhxebto, rspongyqdt - gorkenwmay) View more | - | 07 Apr 2014 | ||
(PANVAC-V + PANVAC-F + GM-CSF) | tyvkbmrbux = jibvfkwbii zmofmbadoa (cwbuhxebto, xzcfltgbbp - zhvllwwbaa) View more | ||||||
Phase 2 | 48 | (Arm I - PANVAC + Docetaxel) | qmrphttspr(nuuvzzowhd) = zxnzcisbbv nklioouheg (uunykjxawm, tfclrbamfp - aamkmeuoob) View more | - | 27 Jun 2013 | ||
(Arm II - Docetaxel Alone) | qmrphttspr(nuuvzzowhd) = hgkzecjgir nklioouheg (uunykjxawm, gtjdgvsawe - ifokbkqrxv) View more |